Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma

Hae-Sim Park (1), Sang Haak Lee (2), Sook Young Lee (3), Mi-Kyeong Kim (4), Byung Jae Lee (5), Viktoria Werkström (6), Peter Barker (7), James G. Zangrilli (7)

1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, St. Paul's Hospital, College of Medicine, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea
3Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
4Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
5Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea
6AstraZeneca, Gothenburg, Sweden
7AstraZeneca, Gaithersburg, MD, USA

ABSTRACT

Purpose: In the Phase III SIROCCO trial (NCT01928771), benralizumab significantly reduced asthma exacerbations and improved lung function and symptoms for patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to evaluate efficacy and safety of benralizumab for Korean patients in SIROCCO.

Methods: SIROCCO was a randomized, double-blind, parallel-group, placebo-controlled trial of 1,204 patients aged 12–75 years with severe asthma uncontrolled by high-dosage inhaled corticosteroids/long-acting β2-agonists (ICS/LABA). Patients received benralizumab 30 mg every 4 weeks (Q4W) or every 8 weeks (Q8W; first 3 doses Q4W) or placebo Q4W for 48 weeks. The primary analysis population comprised patients with blood eosinophil counts ≥ 300 cells/µL. This subgroup analysis evaluated Korean patients from this group.

Results: Of 122 Korean patients randomized, 86 had blood eosinophil counts ≥ 300 cells/µL. Benralizumab reduced the annual asthma exacerbation rate by 70% (Q4W: rate estimate 0.79, rate ratio 0.30 [95% confidence interval {CI}, 0.13–0.65], nominal P = 0.003; n = 28) and 85% (Q8W: rate estimate 0.40, rate ratio 0.15 [95% CI, 0.06–0.36], nominal P < 0.001; n = 30) vs. placebo (rate estimate 2.67, n = 28). Prebronchodilator forced expiratory volume in 1 second was increased with benralizumab treatment by 0.270 L (Q4W: 95% CI, 0.039–0.500, nominal P = 0.023; n = 28) and 0.362 L (Q8W: 95% CI, 0.143–0.582, nominal P = 0.002; n = 30) vs. placebo (n = 27). Total asthma symptom score was similar for patients receiving either benralizumab Q4W (−0.27 [95% CI, −0.83 to 0.30], nominal P = 0.356; n = 27) or benralizumab Q8W (0.10 [95% CI, −0.44 to 0.65], nominal P = 0.708; n = 30) vs. placebo (n = 28). Drug-related adverse events were experienced by 2%, 8%, and 5% of patients in the placebo, benralizumab Q4W, and benralizumab Q8W arms.

Conclusions: Benralizumab reduced annual asthma exacerbation rates, increased lung function, and was well-tolerated by Korean patients with severe, uncontrolled eosinophilic asthma.

Keywords: Asthma; benralizumab; eosinophils; Korea; receptors, interleukin-5
INTRODUCTION

Asthma affects approximately 315 million people worldwide, and 5%–10% of them are estimated to have severe or uncontrolled asthma. In South Korea, approximately 1.8 million people were diagnosed with asthma in 2014, with a prevalence of 36.3 per 1,000 people. Trends in the prevalence of asthma in South Korea are similar to those observed in Western developed countries. Current guidelines in South Korea recommend maintenance treatment with medium- to high-dosage inhaled corticosteroids and long-acting β2-agonists (ICS/LABA) for patients with severe asthma to control their symptoms. Despite the availability of ICS/LABA therapy, many patients’ symptoms remain uncontrolled, resulting in more frequent hospitalizations, increased morbidity, and reduced health-related quality of life. Therefore, additional well-tolerated and effective treatment options are needed.

Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that has recently been approved for the treatment of severe asthma in the United States, Europe, Japan, and Canada. In the United States, benralizumab is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Benralizumab targets eosinophilic inflammation, which is present in about 50% of patients with asthma and is associated with decreased lung function and increased disease severity, exacerbation frequency, and symptom burden. Benralizumab induces the direct, rapid, and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity, an apoptotic process of eosinophil elimination involving natural killer cells. In 2 Phase III trials, SIROCCO (NCT01928771) and CALIMA (NCT01914757), benralizumab significantly reduced asthma exacerbations and improved lung function as well as disease control for patients with severe asthma inadequately controlled with high-dosage ICS/LABA and with blood eosinophil counts ≥ 300 cells/µL vs. placebo. For patients with oral corticosteroid (OCS)-dependent asthma, add-on therapy with benralizumab substantially reduced OCS dosages, and many patients receiving benralizumab were able to stop maintenance OCS treatment completely.

In a Phase IIa dose-ranging trial conducted in South Korea and Japan, benralizumab 2, 20, and 100 mg decreased asthma exacerbation frequency and improved lung function and asthma control for Korean and Japanese patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to further characterize the efficacy and safety of benralizumab for Korean patients using data obtained from the SIROCCO Phase III trial.

MATERIALS AND METHODS

Study design and patients

This was an analysis of the subgroup of Korean patients who participated in the SIROCCO trial. Full details of the SIROCCO trial have been published. SIROCCO was a randomized, double-blind, parallel-group, placebo-controlled Phase III trial of 1,204 patients enrolled in 17 countries, including South Korea. This study included patients aged 12-75 years with a history of physician-diagnosed asthma that required treatment with medium- to high-dosage ICS/LABA for at least 12 months before enrollment. Eligible patients had 2 or more asthma exacerbations in the 12 months before enrollment that required systemic corticosteroid treatment or a temporary increase in their usual maintenance OCS dosages. Patients also received treatment with high-dosage ICS/LABA (>500 µg/d fluticasone propionate dry
powder formulation or equivalent total daily dosage) with or without OCS and additional asthma controllers for ≥3 months before enrollment. The study was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use/Good Clinical Practice guidelines and the ethics committee at each participating site.

The SIROCCO trial consisted of an enrollment visit (week −4), screening phase (weeks −4 to 0), randomization (week 0), treatment period (weeks 0–48), and follow-up visit (week 56). Eligible patients were randomized 1:1:1 to receive benralizumab 30 mg by subcutaneous injection every 4 weeks (Q4W) or Q4W for the first three doses then every 8 weeks thereafter (Q8W; placebo was administered at the interim visits Q4W to maintain blinding) or placebo Q4W for 48 weeks (Fig. 1). Benralizumab and placebo were provided by AstraZeneca (Gaithersburg, MD, USA). Patients in the Q4W arm received their last dose of benralizumab at week 44, and patients in the Q8W arm received their last dose of benralizumab at week 40. Patients continued to receive their background asthma controller medications without dosage modification throughout the trial. Patients with blood eosinophil counts ≥ 300 cells/µL and < 300 cells/µL were recruited in a 2:1 ratio.

Study endpoints
The primary efficacy endpoint was the annual rate of asthma exacerbations vs. placebo. An exacerbation was defined as worsening of asthma that led to: 1) the use of systemic corticosteroids (or a temporary increase in background OCS dosages) for ≥3 days or a single injection of corticosteroids, 2) an emergency department or urgent care visit for < 24 hours because of asthma that required use of systemic corticosteroids, or 3) an inpatient hospitalization for ≥24 hours because of asthma. Worsening of asthma was defined as any new or increased asthma signs or symptoms that were concerning to the patient or related to an Asthma Daily Diary alert.

The key multiplicity-protected secondary endpoints in the main trial were prebronchodilator forced expiratory volume in 1 second (FEV1) and total asthma symptom score. The primary and key secondary endpoints included patients with blood eosinophil counts ≥ 300 cells/µL. Spirometry was conducted at the study centers. Patients recorded their asthma symptoms and results of peak expiratory flow measurements (taken using a handheld spirometric device) twice daily in the Asthma Daily Diary using an electronic patient-reported outcomes device. The Asthma Daily Diary was completed by patients in
the morning upon waking and in the evening before going to bed. The morning and evening assessments included questions on asthma symptoms, night-time awakenings, and rescue medication use. The total daily asthma symptom score was a composite of the morning and evening responses, scored on a 0 to 6 scale. Greater scores indicated a greater burden of symptoms. The electronic patient-reported outcomes devices were programmed to alert patients and study centers when specific criteria were met for asthma worsening on ≥2 consecutive days/nights, including a decrease in morning peak expiratory flow of ≥30% compared with baseline, a ≥50% increase in rescue medication use or 1 new β₂-agonist nebuliser compared with the previous 7 days, nocturnal awakening because of asthma that required rescue medication use, and an increase in total asthma symptom score of ≥2 units above the screening average (or the maximum possible daily score of 6). Safety outcomes included adverse events and serious adverse events.

Statistical analysis
The primary analysis population for this subgroup analysis comprised Korean patients with baseline blood eosinophil counts ≥ 300 cells/µL in the overall SIROCCO trial. Efficacy data are not presented for the population with eosinophil counts < 300 cells/µL because of the small sample size. Annual exacerbation rates were estimated using a negative binomial model that included treatment, number of exacerbations in the previous year, and use of maintenance OCS as covariates. Least squares mean changes from baseline in FEV₁ compared with placebo were estimated using a mixed-effects model for repeated measures analysis, with adjustment for treatment, baseline prebronchodilator FEV₁, use of maintenance OCS, visit, and visit by treatment interaction. Least squares mean changes from baseline in biweekly average total asthma symptom score compared with placebo were also estimated using a mixed-effects model for repeated measures analysis, with adjustment for treatment, baseline total asthma symptom score, use of maintenance OCS, visit, and visit by treatment interaction. Because these analyses were not part of the formal testing strategy, all P-values were nominal. Adverse events were summarized using descriptive statistics. All data analyses were conducted using SAS system version 9.2 or later (SAS Institute Inc., Cary, NC, USA).

RESULTS

Patients
Overall, 2,681 patients participated in the SIROCCO trial. Of these, 177 were Korean, with 122 randomly assigned to receive benralizumab or placebo (Fig. 2). Treatment was completed by 116 Korean patients, with 115 completing the trial. The most common reasons for treatment discontinuation (3 patients) and trial discontinuation (2 patients) were adverse events.

The mean (standard deviation) number of exacerbations experienced in the year before the trial was 3.6 (2.8), 3.1 (2.0), and 2.7 (1.1) for Korean patients receiving placebo, benralizumab Q4W, and benralizumab Q8W, respectively, compared with 2.9 (1.7) for the overall SIROCCO trial population (Table 1). Baseline demographics and clinical characteristics were similar between cohorts; however, the placebo group had more frequent OCS use and decreased lung function compared with the other cohorts, and the placebo and benralizumab Q4W cohorts had greater blood eosinophil counts than the Q8W cohort and overall SIROCCO trial population.
Efficacy

This analysis included Korean patients receiving high-dosage ICS/LABA with baseline blood eosinophil counts ≥ 300 cells/µL. Benralizumab reduced the annual asthma exacerbation rate by 70% with the Q4W regimen (rate 0.79 [95% confidence interval (CI), 0.43–1.46], rate ratio 0.30 [95% CI, 0.13–0.65], nominal \( P = 0.003; \) n = 28) and by 85% with the Q8W regimen (rate 0.40 [95% CI, 0.19–0.82], rate ratio 0.15 [95% CI, 0.06–0.36], nominal \( P < 0.001; \) n = 30) compared with placebo (rate 2.67 [95% CI, 1.61–4.42]; n = 28) (Fig. 3 and Table 2). Prebronchodilator FEV1 increased with benralizumab by 0.270 L (Q4W: 95% CI, 0.039–0.500, nominal \( P = 0.023; \) n = 28) and 0.362 L (Q8W: 95% CI, 0.143–0.582, nominal \( P = 0.002; \) n = 30) relative to placebo (n = 27) at week 48 from baseline (Fig. 4 and Table 2). Improvements in FEV1 with benralizumab vs. placebo were observed as early as 4 weeks after treatment and were maintained throughout the study (Fig. 4). Total asthma symptom score was similar for both benralizumab Q4W (−0.27 [95% CI, −0.83 to 0.30], nominal \( P = 0.356; \) n = 27) and benralizumab Q8W (0.10 [95% CI, −0.44 to 0.65], nominal \( P = 0.708; \) n = 30) compared with placebo (n = 28) at week 48 from baseline (Fig. 5 and Table 2).
Overall, 100 of the 122 (82%) Korean patients experienced 1 or more adverse events (Table 3). The most common adverse events were upper respiratory tract infection (38 patients) and nasopharyngitis (26 patients). The majority of adverse events were not considered related to benralizumab treatment. Adverse events resulting in discontinuation of treatment occurred in 2 patients who received benralizumab (both Q4W, asthenia and cerebral hemorrhage) and 1 patient who received placebo (injection site erythema). Serious adverse events were reported for 9 patients who received benralizumab compared with 11 who received placebo.

Table 1. Patient demographics and baseline clinical characteristics

|                      | Placebo (n = 41) | Benralizumab Q4W (n = 40) | Benralizumab Q8W (n = 41) | SIROCCO (N = 1,204) |
|----------------------|------------------|---------------------------|---------------------------|---------------------|
| Age [yr], median (range) | 56 (32 to 73)    | 53 (24 to 73)             | 50 (26 to 71)             | 51 (12 to 73)       |
| Sex, No. (%)          |                  |                           |                           |                     |
| Male                  | 15 (37)          | 17 (43)                   | 15 (37)                   | 408 (34)            |
| Female                | 26 (63)          | 23 (58)                   | 26 (63)                   | 796 (66)            |
| Smoking history, No. (%) |                |                           |                           |                     |
| Current               | 0 (0)            | 0 (0)                     | 0 (0)                     | 6 (1)               |
| Former                | 11 (27)          | 13 (33)                   | 8 (20)                    | 230 (19)            |
| Never                 | 30 (73)          | 27 (68)                   | 33 (81)                   | 968 (80)            |
| Oral corticosteroid use, No. (%) |               |                           |                           |                     |
| Current               | 11 (27)          | 5 (13)                    | 8 (20)                    | 196 (16)            |
| Former                | 0 (0)            | 0 (0)                     | 0 (0)                     | 0 (0)               |
| Never                 | 30 (73)          | 27 (68)                   | 33 (81)                   | 968 (80)            |
| No. of exacerbations in the last 12 mon, mean (SD) | 3.6 (2.8)       | 3.1 (2.0)                 | 2.7 (1.1)                | 2.9 (1.7)           |
| Prebronchodilator FEV1 [L], mean (SD) | 1.370 (0.378)   | 1.768 (0.495)             | 1.593 (0.494)             | 1.665 (0.573)       |
| Prebronchodilator FEV1 [% PN], mean (SD) | 54.2 (14.5)     | 62.3 (10.3)               | 57.2 (13.8)               | 56.7 (14.6)         |
| Prebronchodilator FEV1/FVC, mean (SD) | 60 (13)         | 63 (11)                   | 60 (13)                   | 61 (13)             |
| Reversibility [%], median (range)* | 13 (−8 to 95)  | 16 (−3 to 64)             | 11 (0 to 127)             | 19 (−26 to 157)     |
| Total asthma symptom score, median (range) | 2.10 (0.20 to 4.00) | 2.10 (0.22 to 4.20) | 2.20 (0.00 to 4.25) | 2.50 (0.00 to 6.00) |
| Blood eosinophil counts [cells/µL], median (range)* | 485 (0 to 1,270) | 500 (0 to 1,830) | 397 (0 to 3,100) | 379 (0 to 3,440) |

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PN, predicted normal; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W); SD, standard deviation.

*Data not available for all Korean patients.

Fig. 3. Effect of benralizumab on annual asthma exacerbation rates for Korean patients with baseline blood eosinophil counts ≥ 300 cells/µL receiving high-dosage ICS/LABA. CI, confidence interval; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W).

*Estimates calculated via a negative binomial model with adjustment for treatment, oral corticosteroid use, and prior exacerbations.
One patient who received benralizumab Q4W died from cerebral hemorrhage, which was considered to be not related to treatment.

**DISCUSSION**

This subgroup analysis evaluated the efficacy and safety of benralizumab 30 mg for Korean patients who participated in the Phase III SIROCCO trial. We found that 48 weeks of benralizumab treatment substantially decreased asthma exacerbations and increased lung

---

**Table 2. Summary of efficacy results for Korean patients in SIROCCO receiving high-dosage ICS/LABA with blood eosinophil counts ≥ 300 cells/µL**

|                        | Korean patients in SIROCCO with blood eosinophil counts ≥ 300 cells/µL (n = 86) |
|------------------------|-------------------------------------------------------------------------------------|
|                        | Placebo (n = 28) | Benralizumab Q4W (n = 28) | Benralizumab Q8W (n = 30) |
| **Annual exacerbation rate** |                        |                          |                          |
| Rate estimate (95% CI) | 2.67 (1.61 to 4.42) | 0.79 (0.43 to 1.46) | 0.40 (0.19 to 0.82) |
| Absolute difference vs. placebo (95% CI) | - | -1.88 (-3.31 to -0.45) | -2.28 (-3.65 to -0.90) |
| Rate ratio vs. placebo (95% CI) | - | 0.30 (0.13 to 0.65) | 0.15 (0.06 to 0.36) |
| \( P \) value vs. placebo | - | 0.003 | < 0.001 |
| **Prebronchodilator FEV1 (L)** |                      |                          |                          |
| No. of patients with EOT data | 27 | 28 | 30 |
| LS mean change | 0.168 | 0.437 | 0.530 |
| LS mean difference vs. placebo (95% CI) | - | 0.270 (0.039 to 0.500) | 0.362 (0.143 to 0.582) |
| \( P \) value vs. placebo | - | 0.023 | 0.002 |
| **Total asthma symptom score** |                      |                          |                          |
| No. of patients with EOT data | 28 | 27 | 30 |
| LS mean change | -0.85 | -1.12 | -0.75 |
| LS mean difference vs. placebo (95% CI) | - | -0.27 (-0.83 to 0.30) | 0.10 (-0.44 to 0.65) |
| \( P \) value vs. placebo | - | 0.356 | 0.708 |

CI, confidence interval; EOT, end of treatment; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; LABA, long-acting \( \beta \)-agonists; LS, least squares; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W).

*Estimates calculated via a negative binomial model with adjustment for treatment, oral corticosteroid use, and prior exacerbations. All \( P \) values are nominal;

†Estimates calculated using a mixed-effects model for repeated measures analysis, with adjustment for treatment, baseline value, oral corticosteroid use at time of randomization, visit, and visit × treatment.
function for Korean patients with baseline blood eosinophil counts ≥ 300 cells/µL receiving high-dosage ICS/LABA. For FEV1, improvements relative to placebo were observed by week 4 of treatment. Asthma symptom improvements with benralizumab treatment were variable, potentially related to the small sample size.

**Table 3. Summary of adverse events (safety analysis set)**

| Korean patients in SIROCCO (N = 122) | Placebo (n = 41) | Benralizumab Q4W (n = 40) | Benralizumab Q8W (n = 41) |
|-----------------------------------|------------------|---------------------------|---------------------------|
| Any AE                            | 33 (80)          | 34 (85)                   | 33 (80)                   |
| AEs in ≥ 10% of patients          |                  |                           |                           |
| Upper respiratory tract infection  | 13 (32)          | 15 (38)                   | 10 (24)                   |
| Nasopharyngitis                   | 10 (24)          | 7 (18)                    | 9 (22)                    |
| Cough                             | 1 (2)            | 3 (8)                     | 5 (12)                    |
| Headache                          | 3 (7)            | 2 (5)                     | 5 (12)                    |
| Any drug-related AE               | 1 (2)            | 3 (8)                     | 2 (5)                     |
| Asthenia                          | 0                | 2 (5)                     | 0                         |
| Liver function test abnormal      | 0                | 1 (3)                     | 0                         |
| Nasopharyngitis                   | 0                | 1 (3)                     | 0                         |
| Nausea                            | 0                | 1 (3)                     | 0                         |
| Chills                            | 0                | 0                         | 1 (2)                     |
| Gingivitis                        | 0                | 0                         | 1 (2)                     |
| Headache                          | 0                | 0                         | 1 (2)                     |
| Injection site erythema           | 1 (2)            | 0                         | 0                         |
| Pain                              | 0                | 0                         | 1 (2)                     |
| Urticaria                         | 0                | 0                         | 1 (2)                     |
| Any AE leading to discontinuation | 1 (2)            | 2 (5)*                    | 0                         |
| Any serious AE                    | 11 (27)          | 5 (13)                    | 4 (10)                    |
| Deaths                            | 0                | 1 (3)†                    | 0                         |
| Injection-site reaction           | 1 (2)            | 0                         | 0                         |

Values are presented as number (%).

AE, adverse event; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W).

*One discontinuation was considered treatment related by the principal investigator (asthenia); †Death (cerebral hemorrhage) was considered not treatment related.
The 85% reduction in exacerbation rate and 0.362-L improvement in lung function with benralizumab Q8W for Korean patients relative to placebo were consistent with those reported for the overall SIROCCO population with blood eosinophil counts ≥ 300 cells/µL (Table 4).¹⁵ In the overall trial population, annual asthma exacerbation rates improved by 45% and 51% with benralizumab Q4W and Q8W, respectively, compared with placebo. Prebronchodilator FEV1 was increased with benralizumab Q4W and Q8W in the overall trial population by 0.106 L and 0.159 L, respectively, compared with placebo at week 48 relative to baseline. Improvements in FEV1 with benralizumab relative to placebo occurred by week 4 of treatment. Total asthma symptom score improved with both dosages of benralizumab relative to placebo by −0.08 (Q4W) and −0.25 (Q8W).

The results of this analysis build on previous benralizumab studies with Asian patients.¹⁸,¹⁹ In a Phase IIa dose-ranging study conducted with Korean and Japanese patients, asthma exacerbations were reduced by 61%, 61%, and 40% after 52 weeks of treatment with benralizumab 2, 20, and 100 mg, respectively, vs. placebo for patients with baseline blood eosinophil counts ≥ 300 cells/µL.¹⁸ Decreased asthma exacerbation rates also were accompanied by increased FEV1 and depletion of blood eosinophils. In an analysis of Japanese patients from the Phase III CALIMA trial, the annual rate of asthma exacerbations was reduced by 66% and 83% with benralizumab Q4W and Q8W, respectively, for patients with blood eosinophil counts ≥ 300 cells/µL relative to placebo.¹⁹ Prebronchodilator FEV1 improved for these patients by 0.334 L and 0.198 L with benralizumab Q4W and Q8W, respectively, after 56 weeks of treatment vs. placebo.

Benralizumab was well-tolerated by Korean patients with a safety profile comparable with that experienced by the overall population in the SIROCCO trial.¹⁵ The most common adverse events in SIROCCO were asthma worsening and nasopharyngitis, whereas the most common adverse events for Korean patients were upper respiratory tract infection and nasopharyngitis. One death occurred in the benralizumab Q4W cohort, which was not considered treatment related.

Overall, our findings suggest that benralizumab efficacy in reducing exacerbations and improving lung function is equal, if not better, for Korean patients than for the overall SIROCCO population with blood eosinophil counts ≥ 300 cells/µL. Because of the small sample size (86 patients) and differences in baseline clinical characteristics between cohorts, larger studies would be needed to confirm that benralizumab has greater efficacy for this patient population. Similarly, further studies are needed to explore if asthma symptoms improve with benralizumab treatment for Korean patients as reported for the overall SIROCCO population and to verify the reported safety profile. Because of the small sample size, the efficacy of benralizumab for patients with blood eosinophil counts < 300 cells/µL could not be evaluated. Benralizumab efficacy has been demonstrated for patients with high-dosage ICS/LABA with baseline blood eosinophil counts ≥ 300 cells/µL in the Korean and overall SIROCCO trial populations (benralizumab vs. placebo) (Table 4).

### Table 4. Summary of efficacy results for patients receiving high-dosage ICS/LABA with baseline blood eosinophil counts ≥ 300 cells/µL in the Korean and overall SIROCCO trial populations (benralizumab vs. placebo)

| Korean patients in SIROCCO* | SIROCCO overall patient population† |
|-----------------------------|-------------------------------------|
| Benralizumab Q4W (n = 28)   | Benralizumab Q8W (n = 30)           |
| Reduction in annual exacerbation rate (%) | ↓70† | ↓85† |
| Increase in prebronchodilator FEV1 (L) | ↑0.270§ | ↑0.362† |
| Change in total asthma symptom score | ↑0.28 | ↑0.07 | ↑0.106§ | ↑0.159† |

FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; LABA, long-acting β₂-agonists; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W).

*All P values are nominal; †P value < 0.001; §P value ≥ 0.001 to ≤ 0.01; ‡P value > 0.01 to ≤ 0.05.
blood eosinophil counts < 300 cells/μL in studies using pooled results from SIROCCO and CALIMA. Studies of this Korean patient population with blood eosinophil counts < 300 cells/μL, along with additional biomarkers for eosinophilic airway inflammation, would need to be performed to confirm benralizumab efficacy for these patients.

Consistent with findings for the overall SIROCCO population, benralizumab 30 mg Q4W and Q8W decrease asthma exacerbations and improve lung function with acceptable safety profiles for Korean patients with severe, uncontrolled eosinophilic asthma.

ACKNOWLEDGMENTS

The SIROCCO trial was funded by AstraZeneca (Gaithersburg, MD, USA) and Kyowa Hakko Kirin (Tokyo, Japan). Hae-Sim Park, Sang Haak Lee, Sook Young Lee, Mi-Kyeong Kim, and Byung Jae Lee were AstraZeneca investigators for the SIROCCO study. Viktoria Werkström, Peter Barker, and James G. Zangrilli are employees of AstraZeneca. All authors contributed to study design; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. We would like to thank Yanping Wu, PhD, of AstraZeneca (Gaithersburg, MD, USA) for support of statistical analysis. We would like to thank the investigators in Korea who participated in the SIROCCO trial for their contributions: Sang-Heon Cho, Seoul National University Hospital; You Sook Cho, Asan Medical Center; Young Joo Cho, Ewha Womans University Mokdong Hospital; Gyu-Young Hur, Korea University Guro Hospital; Heekyoo Kim, Kosin University Gospel Hospital; Joo-Hee Kim, Hallym University Sacred Heart Hospital; Mi-Kyeong Kim, Chungbuk National University Hospital; Young Il Koh, Chonnam National University Hospital; Byung Jae Lee, Sungkyunkwan University School of Medicine; Jaechun Lee, Jeju National University Hospital; Sang Haak Lee, St. Paul’s Hospital, The Catholic University of Korea; Sang Pyo Lee, Gachon University Gil Hospital; Soo Keol Lee, Dong-A University Hospital; Sook Young Lee, The Catholic University of Korea, Seoul St. Mary’s Hospital; Choon-Sik Park, SoonChunHyang University Hospital Bucheon; Hae-Sim Park, Ajou University Hospital; Jung Won Park, Yonsei University Severance Hospital; Ah Young Shin, The Catholic University of Korea Incheon St. Mary’s Hospital; Kwang Ha Yoo, Konkuk University Medical Center; HyoungKyu Yoon, St. Mary’s Hospital. We would also like to thank the health care providers, research staff, and patients who participated in the SIROCCO trial. Editorial support was provided by Alan Saltzman, PhD, of JK Associates, Inc. (Conshohocken, PA, USA), and Michael A. Nissen, ELS, of AstraZeneca (Gaithersburg, MD, USA). This support was funded by AstraZeneca.

REFERENCES

1. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12:204. [PUBMED] [CROSSREF]
2. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73. [PUBMED] [CROSSREF]
3. Kim BK, Kim JY, Kang MK, Yang MS, Park HW, Min KU, et al. Allergies are still on the rise? A 6-year nationwide population-based study in Korea. Allergol Int 2016;65:186-91. [PUBMED] [CROSSREF]
4. Kim DK, Park YB, Oh YM, Jung KS, Yoo JH, Yoo KH, et al. Korean asthma guideline 2014: summary of major updates to the Korean asthma guideline 2014. Tuberc Respir Dis (Seoul) 2016;79:111-20. PUBMED | CROSSREF

5. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139-51. PUBMED | CROSSREF

6. AstraZeneca. Fasenra™ (benralizumab) prescribing information [Internet]. Wilmington, DE: AstraZeneca; 2017 [cited 2018 Jan 10]. Available from: https://www.azpicentral.com/fasenra/fasenra_pi.pdf#page=1.

7. AstraZeneca. Fasenra™ (benralizumab) summary of product characteristics [Internet]. Södertälje: AstraZeneca; 2018 [cited 2018 Mar 13]. Available from: http://ec.europa.eu/health/documents/community-register/2018/20180108139598/anx_139598_en.pdf.

8. AstraZeneca. Fasenra receives approval in Japan [Internet]. Wilmington, DE: AstraZeneca; 2018 [cited 2018 Jan 19]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-receives-approval-in-japan-09012018.html.

9. AstraZeneca. Fasenra™ (benralizumab) product monograph [Internet]. Mississauga: AstraZeneca Canada Inc.; 2018 [cited 2018 May 24]. Available from: http://ec.europa.eu/health/documents/community-register/2018/20180108139598/anx_139598_en.pdf.

10. Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc 2013;10 Suppl:S143-9. PUBMED | CROSSREF

11. Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy 2016;9:142.

12. Talini D, Novelli F, Bacci E, Bartoli M, Cianchetti S, Costa F, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open 2015;5:e005748.

13. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344-1353.e2.

14. Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med 2016;111:219.

15. Bleecker ER, FitzGerald JM, Chanez P, Papai A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27.

16. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41.

17. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017;376:2448-58.

18. Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol 2016;169:135-45.

19. Ohta K, Adachi M, Tohda Y, Kamei T, Kato M, Mark Fitzgerald J, et al. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int 2018;67:266-72.

20. Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III Sirocco and Calima studies. Curr Med Res Opin 2017;33:1605-13.

21. FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the Sirocco and Calima studies. Lancet Respir Med 2018;6:51-64. PUBMED | CROSSREF

https://e-aair.org

https://doi.org/10.4168/aair.2019.11.4.508